Effect of 2 br-alpha-ergocryptin (CB 154) on serum prolactin and the clinical picture in a case of progressive gigantomastia in pregnancy.
A 24 year old woman who had epilepsy since the age of 7 years and who was still using antiepileptics, developed an excessive mamary growth (gigantomastia) during pregnancy. Treatment with CB 154 (Sandoz), 2 Br-alpha-ergocryptin in a dose of 2.5 mg three times a day from the 27th week of pregnancy, resulted in prompt improvement with a corresponding decrease in the plasma prolactin, return of the breast temperature to normal, and disappearance of the EEG-abnormalities. After parturition and subsequent mammoplasty the woman soon became pregant again. During this pregnancy, which terminated in the birth of a normal child, treatment with CB 154 was started early and continued throughout pregnancy with success and without side effects.
D000328:Adult; D001941:Breast Diseases / Q000097:blood / Q000188:drug therapy* / Q000601:surgery; D001971:Bromocriptine / Q000627:therapeutic use*; D002220:Carbamazepine / Q000009:adverse effects / Q000627:therapeutic use; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use; D004833:Epilepsy, Temporal Lobe / Q000188:drug therapy; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008617:Mephenytoin / Q000009:adverse effects / Q000627:therapeutic use; D010634:Phenobarbital / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011388:Prolactin / Q000097:blood
D004873:Ergolines; D002220:Carbamazepine; D001971:Bromocriptine; D011388:Prolactin; D003975:Diazepam; D008617:Mephenytoin; D010634:Phenobarbital